LifeSci Capital analyst Charles Zhu has maintained their bullish stance on CBIO stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Charles Zhu has given his Buy rating due to a combination of factors including Crescent Biopharma’s strategic positioning and promising pipeline developments. The company is on track with its key milestones, notably the anticipated IND filing for CR-001 by the end of 2025, which is expected to replicate the cooperative pharmacology of a successful existing drug, potentially leading to early clinical data by the second half of 2026.
Additionally, the recent hiring of an experienced Chief Scientific Officer, Jan Pinkas, is expected to bolster the company’s capabilities in advancing its ADC programs, including CR-002 and CR-003. The industry interest in PD-(L)1 x VEGF bispecifics remains strong, providing a favorable backdrop for Crescent Biopharma’s strategic initiatives. With a solid cash position of $152.6 million as of mid-2025, the company is well-funded to support its operations through 2027, further supporting the Buy recommendation.